Event
Connect with Quotient Sciences at the upcoming 14th Drug Delivery and Formulation Summit in Berlin from 31st May to 2nd June.
Schedule a meeting
We're here to help you with your drug development challenges
Ask the Experts
Talk to our scientific panel
Whether your question is associated with optimizing your formulation or manufacturing process or planning your clinical pharmacology study, we are here to help.
Our experts have insight into a variety of topics, including:
- Minimizing chemistry costs and moving drug substance supply off the critical path
- Transitioning between drug substance and drug product manufacturing
- Selecting the best formulation technology for poorly soluble molecules
- Meeting clinical trial program needs while reducing cost and waste
- Ensuring maximum flexibility in clinical manufacturing and batch sizes
- Using real-time clinical data to make better formulation decisions
Learn more about our experience and ask our team a question today.
Meet our Experts
More from our team
-
Thought LeadershipStuart McDougall: European Bioanalysis Forum Workshop ContributionStuart McDougall, Quotient Sciences' Principal Research Fellow of Bioanalytical Services, contributes to the European Bioanalysis Forum Workshop on the Harmonized Implementation of the ICH M10 Guideline.
-
Thought LeadershipGareth Jenkins Contributes to Chemistry Today Panel Discussion on Flow ChemistryGareth Jenkins, VP Science and Technology, Candidate Development Services at Quotient Sciences, Contributes to Chemistry Today Panel Discussion on Flow Chemistry. Read it here.
-
Thought LeadershipAndy Lewis speaks about modified-release dosage forms in Drug Development & DeliveryAndy Lewis, Vice President, Pharmaceutical Sciences, has written an article for Drug Development & Delivery entitled, "Alternative Strategies for Development of Modified-Release Dosage Forms"
-
Thought LeadershipDCAT Value Chain Insights - CDMO Roundtable: Managing Orphan Drug ProjectsRoundtable Interview with Paul Quigley, Principal Research Fellow, Drug Substance,& John McDermott, Executive Drug Development Consultant. Low-volume drugs, such as orphan drugs, present challenges in achieving favorable production economics and in managing the projects themselves. A roundtable of CDMOs provides perspectives on those challenges and best practices to resolve them.
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.